肝移植作为治疗不可切除肝结直肠癌的替代方案:推进治疗算法

IF 3.6 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Badi Rawashdeh , Richard Bell , Abdul Hakeem , Raj Prasad
{"title":"肝移植作为治疗不可切除肝结直肠癌的替代方案:推进治疗算法","authors":"Badi Rawashdeh ,&nbsp;Richard Bell ,&nbsp;Abdul Hakeem ,&nbsp;Raj Prasad","doi":"10.1016/j.hbpd.2023.12.002","DOIUrl":null,"url":null,"abstract":"<div><p>Colorectal cancer is a leading cause of cancer-related mortality, with nearly half of the affected patients developing liver metastases<span><span>. For three decades, liver resection (LR) has been the primary curative strategy, yet its applicability is limited to about 20% of cases. </span>Liver transplantation<span> (LT) for unresectable metastases<span><span> was attempted unsuccessfully in the 1990s, with high rates of perioperative death and recurrence. There is now more interest in this strategy due to improvements in systemic therapies and surgical techniques. A significant study conducted by the Oslo group showed that patients receiving liver transplants had a 60% chance of survival after five years. Significantly better results have been achieved by using advanced imaging for </span>risk stratification<span> and further refining selection criteria, especially in the Norvegian SECA trials. This review carefully charts the development and history of LT as a treatment option for colorectal cancer liver metastases. The revolutionary path from the early days of exploratory surgery to the current situation of cautious optimism is traced, highlighting the critical clinical developments and improved patient selection standards that have made LT a potentially curative treatment for such challenging very well selected cases.</span></span></span></span></p></div>","PeriodicalId":55059,"journal":{"name":"Hepatobiliary & Pancreatic Diseases International","volume":"23 2","pages":"Pages 154-159"},"PeriodicalIF":3.6000,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Liver transplantation as an alternative for the treatment of non-resectable liver colorectal cancer: Advancing the therapeutic algorithm\",\"authors\":\"Badi Rawashdeh ,&nbsp;Richard Bell ,&nbsp;Abdul Hakeem ,&nbsp;Raj Prasad\",\"doi\":\"10.1016/j.hbpd.2023.12.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Colorectal cancer is a leading cause of cancer-related mortality, with nearly half of the affected patients developing liver metastases<span><span>. For three decades, liver resection (LR) has been the primary curative strategy, yet its applicability is limited to about 20% of cases. </span>Liver transplantation<span> (LT) for unresectable metastases<span><span> was attempted unsuccessfully in the 1990s, with high rates of perioperative death and recurrence. There is now more interest in this strategy due to improvements in systemic therapies and surgical techniques. A significant study conducted by the Oslo group showed that patients receiving liver transplants had a 60% chance of survival after five years. Significantly better results have been achieved by using advanced imaging for </span>risk stratification<span> and further refining selection criteria, especially in the Norvegian SECA trials. This review carefully charts the development and history of LT as a treatment option for colorectal cancer liver metastases. The revolutionary path from the early days of exploratory surgery to the current situation of cautious optimism is traced, highlighting the critical clinical developments and improved patient selection standards that have made LT a potentially curative treatment for such challenging very well selected cases.</span></span></span></span></p></div>\",\"PeriodicalId\":55059,\"journal\":{\"name\":\"Hepatobiliary & Pancreatic Diseases International\",\"volume\":\"23 2\",\"pages\":\"Pages 154-159\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2023-12-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatobiliary & Pancreatic Diseases International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1499387223002400\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatobiliary & Pancreatic Diseases International","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1499387223002400","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

结直肠癌是导致癌症相关死亡的主要原因,近一半的患者会出现肝转移。三十年来,肝切除术(LR)一直是主要的治愈策略,但其适用范围仅限于约 20% 的病例。20 世纪 90 年代,人们曾尝试对无法切除的转移灶进行肝移植(LT),但未获成功,围手术期的死亡率和复发率都很高。现在,由于系统疗法和手术技术的改进,人们对这一策略有了更多的兴趣。奥斯陆小组进行的一项重要研究显示,接受肝移植的患者五年后的存活率为 60%。通过使用先进的成像技术进行风险分层,并进一步完善选择标准,特别是在挪威的SECA试验中,取得了明显更好的效果。这篇综述仔细描绘了LT作为结直肠癌肝转移治疗方案的发展和历史。文章追溯了从早期的探索性手术到目前的谨慎乐观的革命性道路,强调了关键的临床发展和患者选择标准的改进,这些都使LT成为一种可能治愈的治疗方法,适用于这类极具挑战性的、经过严格筛选的病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Liver transplantation as an alternative for the treatment of non-resectable liver colorectal cancer: Advancing the therapeutic algorithm

Colorectal cancer is a leading cause of cancer-related mortality, with nearly half of the affected patients developing liver metastases. For three decades, liver resection (LR) has been the primary curative strategy, yet its applicability is limited to about 20% of cases. Liver transplantation (LT) for unresectable metastases was attempted unsuccessfully in the 1990s, with high rates of perioperative death and recurrence. There is now more interest in this strategy due to improvements in systemic therapies and surgical techniques. A significant study conducted by the Oslo group showed that patients receiving liver transplants had a 60% chance of survival after five years. Significantly better results have been achieved by using advanced imaging for risk stratification and further refining selection criteria, especially in the Norvegian SECA trials. This review carefully charts the development and history of LT as a treatment option for colorectal cancer liver metastases. The revolutionary path from the early days of exploratory surgery to the current situation of cautious optimism is traced, highlighting the critical clinical developments and improved patient selection standards that have made LT a potentially curative treatment for such challenging very well selected cases.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.40
自引率
6.10%
发文量
152
审稿时长
3.0 months
期刊介绍: Hepatobiliary & Pancreatic Diseases International (HBPD INT) (ISSN 1499-3872 / CN 33-1391/R) a bimonthly journal published by First Affiliated Hospital, Zhejiang University School of Medicine, China. It publishes peer-reviewed original papers, reviews and editorials concerned with clinical practice and research in the fields of hepatobiliary and pancreatic diseases. Papers cover the medical, surgical, radiological, pathological, biochemical, physiological and historical aspects of the subject areas under the headings Liver, Biliary, Pancreas, Transplantation, Research, Special Reports, Editorials, Review Articles, Brief Communications, Clinical Summary, Clinical Images and Case Reports. It also deals with the basic sciences and experimental work. The journal is abstracted and indexed in SCI-E, IM/MEDLINE, EMBASE/EM, CA, Scopus, ScienceDirect, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信